Cargando…

Pazopanib in the management of advanced soft tissue sarcomas

Therapy of soft tissue sarcomas represents an area of significant unmet need in oncology. Angiogenesis has been explored as a potential target both preclinically and clinically, with suggestions of activity. Pazopanib is a multitargeted tyrosine kinase inhibitor with prominent antiangiogenic effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cranmer, Lee D, Loggers, Elizabeth T, Pollack, Seth M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907704/ https://www.ncbi.nlm.nih.gov/pubmed/27354810 http://dx.doi.org/10.2147/TCRM.S84792

Ejemplares similares

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Propranolol for the treatment of vascular sarcomas
por: Wagner, Michael J, et al.
Publicado: (2018)

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2014)

Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021)

Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma
por: Alshamsan, Bader, et al.
Publicado: (2021)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California
por: Seto, Tiffany, et al.
Publicado: (2019)

Effect of Acid‐Suppressive Strategies on Pazopanib Efficacy in Patients With Soft‐Tissue Sarcoma
por: Pisano, Sorana G., et al.
Publicado: (2019)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
por: Hong, Jung Yong, et al.
Publicado: (2023)

Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years
por: Shido, Yoji, et al.
Publicado: (2017)

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
por: Groenland, Stefanie L., et al.
Publicado: (2018)

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
por: Kim, Sang Kyum, et al.
Publicado: (2021)

Immune-Based Therapies for Sarcoma
por: Pollack, Seth M., et al.
Publicado: (2011)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
por: Que, Yi, et al.
Publicado: (2018)

Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
por: Nakano, Kenji, et al.
Publicado: (2016)

Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018)

Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
por: Aoyama, Takeshi, et al.
Publicado: (2023)

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
por: Verheijen, R. B., et al.
Publicado: (2017)

Phase III Soft Tissue Sarcoma Trials: Success or Failure?
por: Lee, Alexander T. J., et al.
Publicado: (2017)

Management of Advanced Adult Soft Tissue Sarcoma
por: Bramwell, Vivien H. C.
Publicado: (2003)

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
por: Shimada, Eijiro, et al.
Publicado: (2021)

Multidisciplinary Management of Soft Tissue Sarcoma
por: Nystrom, Lukas M., et al.
Publicado: (2013)

Lingual alveolar soft part sarcoma responsive to pazopanib: A case report
por: Yoshihiro, Tomoyasu, et al.
Publicado: (2017)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
por: Ray-Coquard, Isabelle, et al.
Publicado: (2017)

Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature
por: Nakahara, Yoshiro, et al.
Publicado: (2017)

Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma
por: Sato, Yasuyoshi, et al.
Publicado: (2021)

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
por: Minot-This, Marie-Sophie, et al.
Publicado: (2022)

Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
por: Cranmer, Lee D
Publicado: (2019)

Management of extremity soft tissue sarcomas
por: Puri, Ajay, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_62smlddobdc46ga7m8m3njg17c